BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 25, 2010
View Archived Issues
Biogen and Abbott Start Phase III Trial of MS Antibody Daclizumab
Biogen Idec Inc. and Abbott kicked off a Phase III trial comparing their anti-IL-2 antibody daclizumab to Biogen's Avonex (interferon beta-1a) in relapsing-remitting multiple sclerosis. (BioWorld Today)
Read More
NormOxys Gets $17.5M Series B to Fund Cardio, Cancer Studies
Read More
'Vino' What All Start-ups Want: Fated Partners Linking at C21
Read More
NewCo News: Immunome Harnessing Immune System's Natural Curative Ability
Read More
Corrections & Clarifications
Read More
Other News To Note
Read More
Stock Movers
Read More
Clinic Roundup
Read More